Interim report, May–July 2023/24
Strong margin expansion
We continued the improving trend from the previous quarters and began our fiscal year with strong performance. We gained market shares and converted a strong order backlog resulting in good revenue growth and strong margin expansion.
Gustaf Salford
President and CEO
First quarter
• Gross order intake decreased by 1 percent to SEK 3,839 M (3,871), corresponding to a 7 percent decrease in constant exchange rates
• Net sales increased by 15 percent to SEK 3,828 M (3,327), corresponding to an 8 percent increase in constant exchange rates
• Adjusted gross margin amounted to 41.6 percent (38.9)
• Adjusted operating income (Adjusted EBIT) amounted to SEK 427 M (132), corresponding to an adjusted EBIT margin of 11.2 percent (4.0)
• Earnings per share was SEK 0.62 (0.16) before/ after dilution
• Adjusted earnings per share was SEK 0.65 (0.19) before/after dilution
• Cash flow after continuous investments amounted to SEK -900 M (-594)
• At today’s AGM the Board of Directors proposes a dividend of SEK 2.40 (2.40) per share (paid in two installments) for the fiscal year 2022/23. This corresponds to 97 percent (79) of the net income
| Group summary | Q1 | 12 months | ||||||
| SEK M | 2023/24 | 2022/23 | Δ | RTM | 2022/23 | Δ | ||
| Gross order intake | 3,839 | 3,871 | -7% | 1 | 20,112 | 20,143 | 0% | 2 |
| Net sales | 3,828 | 3,327 | 8% | 1 | 17,370 | 16,869 | 6% | 2 |
| Adjusted gross margin 3 | 41.6% | 38.9% | 2.6 ppts | 38.7% | 38.1% | 0.6 ppts | ||
| Adjusted EBITDA 4 | 707 | 393 | 80% | 3,120 | 2,806 | 11% | ||
| Adjusted EBITDA-margin 4 | 18.5% | 11.8% | 6.7 ppts | 18.0% | 16.6% | 1.3 ppts | ||
| Adjusted EBIT 5 | 427 | 132 | 224% | 2,038 | 1,743 | 17% | ||
| Adjusted EBIT margin 5 | 11.2% | 4.0% | 7.2 ppts | 11.7% | 10.3% | 1.4 ppts | ||
| Gross margin | 41.5% | 38.7% | 2.8 ppts | 38.3% | 37.6% | 0.7 ppts | ||
| EBITDA | 693 | 379 | 83% | 2,911 | 2,597 | 12% | ||
| EBITDA-margin | 18.1% | 11.4% | 6.7 ppts | 16.8% | 15.4% | 1.4 ppts | ||
| EBIT | 412 | 117 | 252% | 1,726 | 1,431 | 21% | ||
| EBIT margin | 10.8% | 3.5% | 7.2 ppts | 9.9% | 8.5% | 1.5 ppts | ||
| Cash flow after continuous investments | -900 | -594 | -51% | 94 | 400 | -76% | ||
| Adjusted earnings per share before/after dilution, SEK 6 | 0.65 / 0.65 | 0.19 / 0.19 | 251% | 3.57 / 3.57 | 3.11 / 3.10 | 15% | ||
| Earnings per share before/after dilution, SEK | 0.62 / 0.62 | 0.16 / 0.16 | 299% | 2.94 / 2.93 | 2.47 / 2.47 | 19% | ||
1 Compared to last fiscal year based on constant exchange rates.
2 Compared to last rolling twelve months period Aug 2021 – Jul 2022 based on constant currency.
3 Adjusted gross margin = Gross margin excluding items affecting comparability attributable to the Cost-reduction Initiative within the Resilience and Excellence Program, see page 26.
4 Adjusted EBITDA = EBITDA excluding items affecting comparability attributable to the Cost-reduction Initiative within the Resilience and Excellence Program, see page 27.
5 Adjusted EBIT = Operating income (EBIT) excluding items affecting comparability attributable to the Cost-reduction Initiative within the Resilience and Excellence Program, see page 27.
6 Adjusted earnings per share = Net income attributable to Parent Company shareholders, excluding items affecting comparability attributable to the Cost-reduction Initiative, in relation to the weighted average number of shares (excluding treasury shares), see page 28.
# # #
For further information, please contact:
Tobias Hägglöv, CFO
Tel: +46 76 107 4799, e-mail: tobias.hagglov@elekta.com
Time zone: CET: Central European Time
Cecilia Ketels, Head of Investor Relations
Tel: +46 76 611 76 25, e-mail: cecilia.ketels@elekta.com
Time zone: CET: Central European Time
About Elekta
As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com or follow @Elekta on Twitter.